Deferoxamine mesylate only
Phase 3
Deferoxamine mesylate only is one of 29 therapeutic programs targeting Stroke. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
28
Competitors
Pipeline
Status by Indication[2][1]
Competition
Competitive Landscape
461 competitors in Stroke
#DrugCompanyPhaseTrials
1Activase
RochePreclinical
Deferoxamine mesylate only
TThe George Institute
Phase 3
Zometa
PfizerPreclinical
Folvite
Eli LillyPreclinical
Botox
RRevance Therapeutics, Inc.
Preclinical
Periactin
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Alka-Seltzer
AAbbott
Preclinical
Direct Anticoagulant
BayerPreclinical
Inderal
Mylan Pharmaceuticals IncPreclinical
Botulinum Toxin a
GSKPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Deferoxamine mesylate only. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 3[1]
- Company
- TThe George Institute